Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

IL-17 contributes to CD4-mediated graft-versus-host disease.

Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, Holland AM, Grubin J, Mark NM, Liu C, Iwakura Y, Heller G, van den Brink MR.

Blood. 2009 Jan 22;113(4):945-52. doi: 10.1182/blood-2008-08-172155. Epub 2008 Oct 17.

2.
3.

The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.

Zhao K, Zhao D, Huang D, Song X, Chen C, Pan B, Wu Q, Cao J, Yao Y, Zeng L, Xu K.

Immunobiology. 2013 Dec;218(12):1505-13. doi: 10.1016/j.imbio.2013.05.005. Epub 2013 May 20.

PMID:
23816304
4.

Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M.

J Clin Invest. 1998 Dec 15;102(12):2126-35.

5.

IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.

Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M.

Transplantation. 1994 Dec 27;58(12):1385-93.

PMID:
7809932
6.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

8.

Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.

Min CK, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D, Weisiger E, Ferrara JL, Reddy P.

Blood. 2004 Nov 15;104(10):3393-9. Epub 2004 Jul 27.

9.

Interferon-gamma regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease.

Mauermann N, Burian J, von Garnier C, Dirnhofer S, Germano D, Schuett C, Tamm M, Bingisser R, Eriksson U, Hunziker L.

Am J Respir Crit Care Med. 2008 Aug 15;178(4):379-88. doi: 10.1164/rccm.200711-1648OC. Epub 2008 May 29.

PMID:
18511701
10.

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.

Nat Med. 2003 Sep;9(9):1144-50. Epub 2003 Aug 17.

PMID:
12925844
11.

Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR.

J Clin Invest. 1998 Nov 1;102(9):1742-8.

12.

IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.

Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA, Hagino T, Jagdeo J, Pai CC, Chen M, Blazar BR, Abedi M, Murphy WJ.

J Immunol. 2012 Aug 15;189(4):2033-42. doi: 10.4049/jimmunol.1102853. Epub 2012 Jul 9.

13.

Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning.

Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ.

Biol Blood Marrow Transplant. 2000;6(6):604-12.

14.

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.

Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, LeBon T, Kandeel F, Forman S, Zeng D.

Blood. 2008 Sep 1;112(5):2101-10. doi: 10.1182/blood-2007-12-126987. Epub 2008 Jul 2.

15.

Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.

Shankar G, Bryson JS, Jennings CD, Morris PE, Cohen DA.

Am J Respir Cell Mol Biol. 1998 Feb;18(2):235-42.

PMID:
9476911
16.

Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.

Park MJ, Moon SJ, Lee SH, Yang EJ, Min JK, Cho SG, Yang CW, Park SH, Kim HY, Cho ML.

PLoS One. 2013 Jun 20;8(6):e67171. doi: 10.1371/journal.pone.0067171. Print 2013.

17.

Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells.

Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH.

Biol Blood Marrow Transplant. 2008 Sep;14(9):959-72. doi: 10.1016/j.bbmt.2008.06.007.

19.

T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells.

Sandy AR, Chung J, Toubai T, Shan GT, Tran IT, Friedman A, Blackwell TS, Reddy P, King PD, Maillard I.

J Immunol. 2013 Jun 1;190(11):5818-28. doi: 10.4049/jimmunol.1203452. Epub 2013 May 1.

20.

Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.

Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W, Taylor PA.

J Immunol. 2000 Nov 1;165(9):4901-9.

Supplemental Content

Support Center